[go: up one dir, main page]

MA32075B1 - Composes presentant une activite antagoniste de crth2 - Google Patents

Composes presentant une activite antagoniste de crth2

Info

Publication number
MA32075B1
MA32075B1 MA33081A MA33081A MA32075B1 MA 32075 B1 MA32075 B1 MA 32075B1 MA 33081 A MA33081 A MA 33081A MA 33081 A MA33081 A MA 33081A MA 32075 B1 MA32075 B1 MA 32075B1
Authority
MA
Morocco
Prior art keywords
heteroaryl
aryl
alkyl
independently represent
compounds
Prior art date
Application number
MA33081A
Other languages
Arabic (ar)
English (en)
Inventor
Richard Edward Armer
Eric Roy Pettipher
Mark Whittaker
Graham Michael Wynne
Julia Vile
Frank Schroer
Original Assignee
Oxagen Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0800874A external-priority patent/GB0800874D0/en
Priority claimed from GB0820526A external-priority patent/GB0820526D0/en
Application filed by Oxagen Ltd filed Critical Oxagen Ltd
Publication of MA32075B1 publication Critical patent/MA32075B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)

Abstract

L'invention porte sur des composés représentés par la formule générale (i), dans laquelle w représente chloro ou fluoro ; r1 représente phényle éventuellement substitué par un ou plusieurs substituants choisis parmi halo, -cn, alkyle en c1-c6, -sor3, -so2r3, -so2n(r2)2, -n(r2)2, -nr2c(o)r3, -co2r2, - conr2r3, -no2, -or2, -sr2, -o(ch2)por2, et -o(ch2)po(ch2)qor2, où les r2 représentent chacun indépendamment hydrogène, alkyle en c1-c6, cycloalkyle en c3-c8, aryle ou hétéroaryle ; les r3 représentent chacun indépendamment alkyle en c1-c6, cycloalkyle en c3-c8, aryle ou hétéroaryle ; p et q représentent chacun indépendamment un entier de 1 à 3 ; et sur leurs sels, hydrates, solvates, complexes ou promédicaments pharmaceutiquement acceptables, qui sont utiles dans des compositions administrables par voie orale pour le traitement de maladies allergiques, telles que l'asthme, la rhinite allergique et la dermatite atopique.
MA33081A 2008-01-18 2010-08-13 Composes presentant une activite antagoniste de crth2 MA32075B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0800874A GB0800874D0 (en) 2008-01-18 2008-01-18 Compounds having CRTH2 antagonist activity
GB0820526A GB0820526D0 (en) 2008-11-10 2008-11-10 Compounds having crth2 antagonist activity
PCT/GB2009/000142 WO2009090414A1 (fr) 2008-01-18 2009-01-19 Composés présentant une activité antagoniste de crth2

Publications (1)

Publication Number Publication Date
MA32075B1 true MA32075B1 (fr) 2011-02-01

Family

ID=40473418

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33081A MA32075B1 (fr) 2008-01-18 2010-08-13 Composes presentant une activite antagoniste de crth2

Country Status (24)

Country Link
US (1) US20090186923A1 (fr)
EP (1) EP2250161B1 (fr)
JP (2) JP2011509988A (fr)
KR (1) KR101644170B1 (fr)
CN (1) CN101932571B (fr)
AU (1) AU2009204700B2 (fr)
BR (1) BRPI0906786B1 (fr)
CA (1) CA2712017C (fr)
CY (1) CY1114748T1 (fr)
DK (1) DK2250161T3 (fr)
ES (1) ES2442717T3 (fr)
HR (1) HRP20140045T1 (fr)
IL (1) IL206959A (fr)
MA (1) MA32075B1 (fr)
MX (1) MX2010007833A (fr)
MY (1) MY155133A (fr)
NZ (1) NZ587251A (fr)
PL (1) PL2250161T3 (fr)
PT (1) PT2250161E (fr)
RS (1) RS53142B (fr)
RU (1) RU2503672C2 (fr)
SI (1) SI2250161T1 (fr)
WO (1) WO2009090414A1 (fr)
ZA (1) ZA201005799B (fr)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6962940B2 (en) 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
GB0324763D0 (en) * 2003-10-23 2003-11-26 Oxagen Ltd Use of compounds in therapy
WO2009061681A2 (fr) * 2007-11-06 2009-05-14 Amira Pharmaceuticals, Inc Antagonistes de récepteurs pgd2
WO2009061676A2 (fr) * 2007-11-06 2009-05-14 Amira Pharmaceuticals, Inc. Antagonistes de récepteurs pgd2
US20110124683A1 (en) * 2007-11-13 2011-05-26 Oxagen Limited Use of CRTH2 Antagonist Compounds
US7750027B2 (en) * 2008-01-18 2010-07-06 Oxagen Limited Compounds having CRTH2 antagonist activity
DK2250161T3 (da) * 2008-01-18 2014-01-27 Atopix Therapeutics Ltd Forbindelser med CRTH2-antagonistaktivitet
JP2011509990A (ja) * 2008-01-22 2011-03-31 オキサジェン リミテッド Ｃｒｔｈ２アンタゴニスト活性を有する化合物
US8168673B2 (en) * 2008-01-22 2012-05-01 Oxagen Limited Compounds having CRTH2 antagonist activity
US8168678B2 (en) 2008-02-01 2012-05-01 Panmira Pharmaceuticals, Inc. N,N-disubstituted aminoalkylbiphenyl antagonists of prostaglandin D2 receptors
EP2257536A4 (fr) * 2008-02-14 2011-03-23 Amira Pharmaceuticals Inc Composés diaryliques cycliques en tant qu'antagonistes de récepteurs de prostaglandine d2
WO2009108720A2 (fr) 2008-02-25 2009-09-03 Amira Pharmaceuticals, Inc. Antagonistes des récepteurs d2 de la prostaglandine
EP2268611A2 (fr) * 2008-04-02 2011-01-05 Amira Pharmaceuticals, Inc. Antagonistes d aminoalkylphényle de récepteurs de prostaglandine d<sb>2</sb>
US20110112134A1 (en) * 2008-05-16 2011-05-12 Amira Pharmaceuticals, Inc. Tricyclic Antagonists of Prostaglandin D2 Receptors
JP2011526281A (ja) * 2008-06-24 2011-10-06 アミラ ファーマシューティカルズ，インク． プロスタグランジンｄ２受容体のシクロアルカン［ｂ］インドールアンタゴニスト
MX2010014172A (es) * 2008-07-03 2011-02-22 Amira Pharmaceuticals Inc Antagonistas de receptores de prostaglandina d2.
GB2463788B (en) * 2008-09-29 2010-12-15 Amira Pharmaceuticals Inc Heteroaryl antagonists of prostaglandin D2 receptors
WO2010039977A2 (fr) 2008-10-01 2010-04-08 Amira Pharmaceuticals, Inc. Antagonistes d’hétéroaryle des récepteurs de la prostaglandine d2
US8524748B2 (en) 2008-10-08 2013-09-03 Panmira Pharmaceuticals, Llc Heteroalkyl biphenyl antagonists of prostaglandin D2 receptors
GB2465062B (en) * 2008-11-06 2011-04-13 Amira Pharmaceuticals Inc Cycloalkane(B)azaindole antagonists of prostaglandin D2 receptors
WO2010057118A2 (fr) 2008-11-17 2010-05-20 Amira Pharmaceuticals, Inc. Antagonistes hétérocycliques des récepteurs de la prostaglandine d2
CA2768492A1 (fr) * 2009-07-31 2011-02-03 Panmira Pharmaceuticals, Llc Compositions pharmaceutiques ophtalmiques d'antagonsites du recepteur dp2
CN102596902A (zh) * 2009-08-05 2012-07-18 潘米拉制药公司 Dp2拮抗剂及其用途
CA2782085A1 (fr) 2010-01-06 2011-07-14 Panmira Pharmaceuticals, Llc Antagoniste du dp2 et ses utilisations
PL2558447T3 (pl) 2010-03-22 2015-03-31 Idorsia Pharmaceuticals Ltd Pochodne 3-(heteroaryloamino)-1,2,3,4-tetrahydro-9h-karbazolu i ich zastosowanie jako modulatorów receptora prostaglandyny D2
GB201103837D0 (en) 2011-03-07 2011-04-20 Oxagen Ltd Amorphous (5-Fluoro-2-Methyl-3-Quinolin-2-Ylmethyl-Indol-1-Yl)-acetic acid
US9096595B2 (en) 2011-04-14 2015-08-04 Actelion Pharmaceuticals Ltd 7-(heteroaryl-amino)-6,7,8,9-tetrahydropyrido[1,2-a]indol acetic acid derivatives and their use as prostaglandin D2 receptor modulators
LT2781508T (lt) * 2011-11-17 2019-03-12 Kbp Biosciences Co., Ltd. Azoto turintys kondensuoti žiediniai junginiai, skirti panaudoti kaip crth2 antagonistai
GB201121557D0 (en) 2011-12-15 2012-01-25 Oxagen Ltd Process
SG11201402796SA (en) * 2011-12-16 2014-06-27 Atopix Therapeutics Ltd Combination of crth2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis
CN104487431B (zh) * 2012-07-10 2017-06-09 弗·哈夫曼-拉罗切有限公司 治疗和预防呼吸道合胞体病毒感染的新吲唑类化合物
AR093703A1 (es) 2012-12-04 2015-06-17 Takeda Pharmaceuticals Co Agente profilactico o terapeutico para el sindrome de sjogren
US9872854B2 (en) * 2013-03-14 2018-01-23 Celgene Corporation Methods for the treatment of psoriatic arthritis using apremilast
GB201322273D0 (en) * 2013-12-17 2014-01-29 Atopix Therapeutics Ltd Process
AU2014373683B2 (en) * 2013-12-31 2020-05-07 Rapamycin Holdings, Llc Oral rapamycin nanoparticle preparations and use
HUE039614T2 (hu) 2014-03-17 2019-01-28 Idorsia Pharmaceuticals Ltd Azaindol-ecetsav-származékok és prosztaglandin D2 receptor modulátorokként történõ alkalmazásuk
KR20160133536A (ko) 2014-03-18 2016-11-22 액테리온 파마슈티칼 리미티드 아자인돌 아세트산 유도체 및 프로스타글란딘 d2 수용체 조절제로서의 이의 용도
GB201407820D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
GB201407813D0 (en) * 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
GB201407807D0 (en) * 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
EP3159339B1 (fr) * 2014-06-09 2020-11-25 Sumitomo Chemical Company, Limited Procédé de production d'un composé pyridinique
US10092541B2 (en) 2014-08-15 2018-10-09 Celgene Corporation Methods for the treatment of diseases ameliorated by PDE4 inhibition using dosage titration of apremilast
MX379014B (es) 2015-09-15 2025-03-10 Idorsia Pharmaceuticals Ltd Formas cristalinas.
EP3668832A1 (fr) 2017-08-14 2020-06-24 Allergan, Inc. 3-cyclobutène-1,2-diones 3,4-disubstituées et leur utilisation
CN113330013B (zh) * 2019-01-10 2022-12-27 石药集团中奇制药技术（石家庄）有限公司 杂环化合物盐及其应用
CN114796264A (zh) * 2021-01-27 2022-07-29 北京北工大科技园有限公司 金络合物在制备治疗新型冠状病毒肺炎的药物中的应用
EP4165009A4 (fr) * 2020-06-12 2024-10-02 Nucmito Pharmaceuticals Co., Ltd. Composés d'indène, compositions pharmaceutiques de ceux-ci et leurs applications thérapeutiques
IL304924A (en) 2021-02-10 2023-10-01 Iolyx Therapeutics Inc Methods for ophthalmic delivery of roflumilast
CA3218813A1 (fr) * 2021-05-15 2022-11-24 Nucmito Pharmaceuticals Company Limited Composes indenes, compositions pharmaceutiques a base de ceux-ci et leurs applications therapeutiques
WO2023049809A1 (fr) 2021-09-22 2023-03-30 Iolyx Therapeutics, Inc. Méthodes de traitement de maladies inflammatoires oculaires
CN115192584A (zh) * 2022-06-09 2022-10-18 南方科技大学 一种纳米药物及其制备方法和应用
AU2023381655A1 (en) * 2022-11-16 2025-05-29 Nucmito Pharmaceuticals Co. Ltd. Indene compounds, pharmaceutical compositions thereof, and their therapeutic applications

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3557142A (en) 1968-02-20 1971-01-19 Sterling Drug Inc 4,5,6,7-tetrahydro-indole-lower-alkanoic acids and esters
BE790679A (fr) 1971-11-03 1973-04-27 Ici Ltd Derives de l'indole
GB1407658A (en) 1973-03-06 1975-09-24 Ici Ltd Process for the manufacture of indole derivatives
GB1460348A (en) 1974-02-04 1977-01-06 Ici Ltd Quinazoline derivativesa
DK151884C (da) 1979-03-07 1988-06-13 Pfizer Analogifremgangsmaade til fremstilling af 3-(1-imidazolylalkyl)indolderivater eller farmaceutisk acceptable syreadditionssalte deraf
US4363912A (en) * 1980-12-15 1982-12-14 Pfizer Inc. Indole thromboxane synthetase inhibitors
GB8607294D0 (en) 1985-04-17 1986-04-30 Ici America Inc Heterocyclic amide derivatives
GB9122590D0 (en) 1991-10-24 1991-12-04 Lilly Industries Ltd Pharmaceutical compounds
WO1997046677A1 (fr) 1996-06-05 1997-12-11 Bml, Inc. PROTEINE SPECIFIQUE DU Th2 HUMAIN, GENE (B19) CODANT POUR CETTE PROTEINE, TRANSFORMANT, VECTEUR DE RECOMBINAISON ET ANTICORPS MONOCLONAL S'Y RAPPORTANT
US6916841B2 (en) 1998-02-25 2005-07-12 Genetics Institute, Llc Inhibitors of phospholipase enzymes
IL138711A0 (en) 1998-03-31 2001-10-31 Inst Pharmaceutical Discovery Substituted indolealkanoic acids
TNSN99224A1 (fr) 1998-12-01 2005-11-10 Inst For Pharm Discovery Inc Methodes de reduction des niveaux de glucose et triglyceride en serum et pour suppression de l'antigenese utilisant les acides la indolealkanoique
GB9902461D0 (en) * 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
US6884593B1 (en) 1999-08-23 2005-04-26 Bml, Inc. Method of identifying properties of substance with respect to human prostaglandin D2 receptors
WO2001051849A1 (fr) 2000-01-14 2001-07-19 Koninklijke Philips Electronics N.V. Dispositif d'affichage
US6521659B2 (en) 2000-03-02 2003-02-18 Institute For Pharmaceutical Discovery, Llc Compositions containing a substituted indolealkanoic acid and an angiotensin converting enzyme inhibitor
JP2001247570A (ja) 2000-03-08 2001-09-11 Japan Tobacco Inc インドール酢酸化合物及びその製造方法
US6878522B2 (en) 2000-07-07 2005-04-12 Baiyong Li Methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D2
SE0200356D0 (sv) 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
SE0200411D0 (sv) 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
AU2003231509A1 (en) 2002-05-16 2003-12-02 Shionogi And Co., Ltd. Compound exhibiting pgd 2 receptor antagonism
JPWO2003097042A1 (ja) 2002-05-16 2005-09-15 塩野義製薬株式会社 Ｐｇｄ２受容体拮抗剤
TW200307542A (en) 2002-05-30 2003-12-16 Astrazeneca Ab Novel compounds
SE0201635D0 (sv) 2002-05-30 2002-05-30 Astrazeneca Ab Novel compounds
SE0202241D0 (sv) * 2002-07-17 2002-07-17 Astrazeneca Ab Novel Compounds
US7364647B2 (en) 2002-07-17 2008-04-29 Eksigent Technologies Llc Laminated flow device
ES2401079T3 (es) 2002-12-20 2013-04-16 Amgen Inc. Moduladores del asma y de la inflamación alérgica
JP4324418B2 (ja) 2003-08-05 2009-09-02 株式会社日立国際電気 基板処理装置および半導体デバイスの製造方法
SE0302232D0 (sv) 2003-08-18 2003-08-18 Astrazeneca Ab Novel Compounds
BRPI0415437A (pt) 2003-10-14 2006-12-05 Oxagen Ltd composto, processo para a preparação e uso do mesmo, composição farmacêutica, processo para a preparação da mesma, e, produto
GB0324763D0 (en) * 2003-10-23 2003-11-26 Oxagen Ltd Use of compounds in therapy
BRPI0508579A (pt) 2004-03-11 2007-08-14 Actelion Pharmaceuticals Ltd composto, composição farmacêutica, e, uso de um composto
CA2563707A1 (fr) * 2004-04-20 2005-11-03 Pfizer Inc. Methode de traitement de la douleur neuropathique au moyen d'un antagoniste du recepteur crth2
AU2005286718A1 (en) 2004-09-21 2006-03-30 Wyeth Indole acetic acids exhibiting CRTH2 receptor antagonism and uses thereof
GB0504150D0 (en) 2005-03-01 2005-04-06 Oxagen Ltd Microcrystalline material
GB0505048D0 (en) * 2005-03-11 2005-04-20 Oxagen Ltd Compounds with PGD antagonist activity
PL65781Y1 (pl) 2005-08-16 2012-02-29 Katarzyna Kawczyńska Wkładka kosmetyczna
MX2009000801A (es) * 2006-07-22 2009-02-03 Oxagen Ltd Compuestos que tienen actividad antagonista crth2.
GB0722203D0 (en) * 2007-11-13 2007-12-19 Oxagen Ltd Use of CRTH2 antagonist compounds
DK2229358T3 (da) * 2007-12-14 2011-07-04 Pulmagen Therapeutics Asthma Ltd Indoler og deres terapeutiske anvendelse
DK2250161T3 (da) * 2008-01-18 2014-01-27 Atopix Therapeutics Ltd Forbindelser med CRTH2-antagonistaktivitet

Also Published As

Publication number Publication date
RU2010129027A (ru) 2012-02-27
PT2250161E (pt) 2014-01-21
CA2712017A1 (fr) 2009-07-23
ZA201005799B (en) 2012-01-25
PL2250161T3 (pl) 2014-05-30
ES2442717T3 (es) 2014-02-13
RU2503672C2 (ru) 2014-01-10
US20090186923A1 (en) 2009-07-23
BRPI0906786A2 (pt) 2015-07-14
CN101932571B (zh) 2014-04-23
DK2250161T3 (da) 2014-01-27
EP2250161B1 (fr) 2013-10-16
CY1114748T1 (el) 2016-12-14
IL206959A0 (en) 2010-12-30
AU2009204700B2 (en) 2013-07-04
AU2009204700A1 (en) 2009-07-23
SI2250161T1 (sl) 2014-04-30
HK1145175A1 (en) 2011-04-08
KR20100110361A (ko) 2010-10-12
HRP20140045T1 (hr) 2014-02-14
EP2250161A1 (fr) 2010-11-17
JP2011509988A (ja) 2011-03-31
CN101932571A (zh) 2010-12-29
MY155133A (en) 2015-09-15
WO2009090414A1 (fr) 2009-07-23
NZ587251A (en) 2011-12-22
KR101644170B1 (ko) 2016-08-01
JP2014159465A (ja) 2014-09-04
IL206959A (en) 2014-09-30
CA2712017C (fr) 2016-08-09
MX2010007833A (es) 2010-08-11
RS53142B (sr) 2014-06-30
JP5855162B2 (ja) 2016-02-09
BRPI0906786B1 (pt) 2021-10-05

Similar Documents

Publication Publication Date Title
MA32075B1 (fr) Composes presentant une activite antagoniste de crth2
ES2528797T3 (es) Compuestos de aza-benzotiofenilo y métodos de uso
PE20211203A1 (es) Compuestos para el tratamiento de trastornos dependientes de cinasas
EA201101089A1 (ru) Производные оксадиазола в качестве агонистов рецептора s1p1
AR084976A1 (es) Compuestos de bifenileno sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales
MA40225A (fr) Composés dihydroisoquinolinone substitués
CY1114141T1 (el) Ενωσεις που εχουν ανταγωνιστικη του crth2 δραστηριοτητα
MA37142A3 (fr) Dérivés de dihydro-benzo-oxazine et de dihydro-pyrido-oxazine
EA201170096A1 (ru) Замещенные производные пиримидона
MA33721B1 (fr) Derives sulfonamides heterocycliques utilises comme inhibiteurs de mek
NO20072409L (no) Substituerte n-sulfonylaminobenzyl-2-fenoksy acetamid-forbindelser
MA54386B1 (fr) Modulateurs de trex1
EA201000104A1 (ru) Производные пиримидина, применимые для лечения воспалительных или аллергических патологических состояний
EA201391537A1 (ru) ЭТИНИЛЬНЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ПОЛОЖИТЕЛЬНЫХ АЛЛОСТЕРИЧЕСКИХ МОДУЛЯТОРОВ mGluR5
WO2009118473A3 (fr) Composés dérivés d&#39;azétidines, leur préparation et leur application en thérapeutique
PH12018502012B1 (en) Griseofulvin compound
PL408251A1 (pl) Skondensowane pochodne triazolu jako inhibitory fosfodiesterazy 10A
HRP20041087B1 (hr) Derivati n-acilaminobenzena kao selektivni inhibitori monoamin oksidaze b
RU2012146325A (ru) Терапевтическое средство или профилактическое средство для лечения фибромиалгии
CO6290688A2 (es) Derivados de oxadiazol activos en 1-fosfato de esfingosina
MA29343B1 (fr) Derives de 1,2,4-triazines, leur preparation et leur application en therapeutique humaine
TW200716527A (en) Substituted aminoalkyl-and amidoalkyl-benzopyran derivatives
WO2012107735A3 (fr) Traitement de trouble bipolaire
AR066743A1 (es) Inhibidores no nucleosidos de la transcriptasa inversa
MX2023008250A (es) Compuestos de derivados sustituidos en 4,6 de ip4.